Long-term outcomes with agalsidase alfa enzyme replacement therapy
This is a retrospective analysis of Fabry Outcome Survey data from children/adults (n = 677) receiving agalsidase alfa enzyme replacement therapy for a median of 3 years, examining cerebrovascular, cardiac, and renal morbidity endpoints separately. Cardiac events occurred at younger ages than cerebr...
| Authors: | , , , , , , |
|---|---|
| Format: | article |
| Publication Date: | 2017 |
| Country: | España |
| Institution: | Universitat Autònoma de Barcelona |
| Repository: | Dipòsit Digital de Documents de la UAB |
| Language: | English |
| OAI Identifier: | oai:ddd.uab.cat:186384 |
| Online Access: | https://ddd.uab.cat/record/186384 https://dx.doi.org/urn:doi:10.1016/j.ymgmr.2017.10.008 |
| Access Level: | Open access |
| Keyword: | Egfr, estimated glomerular filtration rate ERT, enzyme replacement therapy FOS, Fabry Outcome Survey LVH, left ventricular hypertrophy NE, not estimable Fabry disease Enzyme replacement therapy Agalsidase alfa Long-term effectiveness |
| Summary: | This is a retrospective analysis of Fabry Outcome Survey data from children/adults (n = 677) receiving agalsidase alfa enzyme replacement therapy for a median of 3 years, examining cerebrovascular, cardiac, and renal morbidity endpoints separately. Cardiac events occurred at younger ages than cerebrovascular or renal events, cerebrovascular events were more frequent in females than males, and males were more likely to experience cardiac and renal events at a younger age than females. |
|---|